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TEXT: 25
We have read with interest the research letter by Javaid et al. in a recent issue of the European 26
Respiratory Journal. 1 The authors aptly note some uncertainty in current World Health 27 Organization (WHO) guidelines. 2 Nevertheless, we question the authors' main assertion that 28 "high prevalence of ofloxacin resistance should not limit the applicability of the new shorter 29 regimen". The shortened regimen has indeed produced promising results in a number of 30 settings, in populations carefully selected for their limited exposure and resistance to second-31 line drugs. [3] [4] [5] That this should be extended to settings with high prevalence of fluoroquinolone 32 resistance, without individual, rapid molecular testing for fluoroquinolone resistance, is not 33 supported by data or WHO. 34
The present sub-national, cross-sectional study shows worryingly high levels of 35 resistance to ofloxacin and other drugs contained in the shortened multidrug-resistant 36 tuberculosis (MDR-TB) regimen. We concur with the authors on the importance of 37 strengthening the public-health response to the various sources of fluoroquinolone-resistant 38 TB in Pakistan. Nevertheless, the presence of ofloxacin resistance, tested at 2 μg·mL −1 , in 39 48.6% of patients does not support widespread applicability of the shortened regimen in this 40 population. More than 50% of the patients in Bangladesh with "high-level" resistance to 41 ofloxacin by this definition had unfavorable treatment outcomes on the shortened regimen. 3 42 Moreover, it is noteworthy that the present study did not report overlapping resistance 43 among these drugs to further inform estimates of the population eligible for the shortened 44 regimen. Since rapid, reliable pyrazinamide testing is not available routinely, any use of the 45 shortened regimen in the presence of high population levels of ofloxacin resistance needs to 46 consider the frequency of concurrent pyrazinamide resistance: according to results from 47 meta-analyses that supported the development of WHO recommendations, the probability of 48
Guglielmetti et al -Ofloxacin resistance and shortened MDR-TB treatment 3 favorable outcomes on the shortened regimen is reduced from 90.3 (95% CI: 87.8-92.4%) 49 among all patients to 67.9% (95% CI: 47.5-84.1%) among patients with isolates resistant to 50 both drugs. 6 The authors assertion that "it is not recommended to base decision-making on 51 the basis of resistance to pyrazinamide and ethambutol" is at odds with these findings and 52
with WHO guidance. The latter recommends avoiding the shortened treatment in patients 53
with "documented or likely resistance to medicines in the regimen" and "in patients infected 54 with strains known or strongly suspected of being resistant to one or more drugs in the shorter 55 MDR-TB treatment regimen (e.g. pyrazinamide) …". 6 56
The authors propose to increase the applicability of the shortened regimen in this and 57 similar settings by: a) increasing the clinical breakpoint for ofloxacin from 2 to 4 μg·mL −1 , b) 58 administering moxifloxacin at high dose, and c) considering resistance to 59 moxifloxacin/gatifloxacin, rather than ofloxacin, as an exclusion criterion for the short course 60 treatment. However, these changes neither resolve the uncertainty in the guidelines nor 61 strengthen the case for the shortened regimen in populations with high prevalence of 62 fluoroquinolone resistance. First, rationale for the proposed increase of MIC for ofloxacin, 63
presumably to serve as a better proxy for resistance to later-generation fluoroquinolones, is 64 not presented; this cut-off is higher than that used for both the national survey and the 65 observational study that demonstrated different clinical outcomes of the shorter regimen in 66 strains with low-level versus high-level fluoroquinolone resistance. 3,7 Second, 67 moxifloxacin/gatifloxacin are already prescribed at high dose (400 to 800 mg/day according 68 to weight group) in some applications of the shortened regimen, so the results showing 69 reduced effectiveness in the presence of resistance to fluoroquinolones and pyrazinamide 70 already factor in this reinforcement. 6 Third, while we agree in principle that usefulness of late-71 generation fluoroquinolones is best guided by drug susceptibility testing (DST) to those 72 drugs-and not by DST to earlier-generation class members 8 -the proposed modification to 73 guidance to rule out moxifloxacin/gatifloxacin resistance is problematic from an operational 74 standpoint; DST to these drugs is infrequently available in high-burden settings (including 75
Pakistan, according to the authors). More practically, rapid molecular tests will be used to 76 assess eligibility. Their careful interpretation to identify individual patients eligible for the 77 shortened regimen will be especially important in settings with known high population levels 78 of fluoroquinolone resistance. Existing data from sequencing suggest that resistance caused 79 by mutations in the QRDR region of gyrA (except 94Ala) is associated with an important 80 increase in poor outcomes on the shortened regimen. 9 Fortunately, there are other options: 81 the advent of delamanid and bedaquiline, 10 as well as other "core" MDR-TB drugs used in 82 conventional regimens offer alternatives to using the shortened regimen in patients in whom 83 its success is likely compromised. Multiple new studies of shortened regimens containing 84 these drugs (Nix-TB [NCT02333799], TB-PRACTECAL [NCT02589782], endTB [NCT02754765]) 85 may generate palatable and effective alternatives. 86
In conclusion, we recommend caution in the introduction of the shortened MDR-TB 87 treatment in settings with high prevalence of resistance to ofloxacin or pyrazinamide; 88 eligibility for shortened treatment should be evaluated individually according to rapid 89 molecular testing and available DST results. 90
